Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aurinia Pharmaceuticals Inc

AUPH ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$15.47

▲ +1.91%

Market Cap $2.06B · Vol 242.10K

Key Metrics

P/E Ratio

6.76

FWD: 13.92

Market Cap

$2.06B

Mid Cap

Div Yield

N/A

EPS Growth

+19.26%

YoY

RSI (14)

53.09

Momentum

Beta

1.40

vs Market

52W High

$19.24

19.59% below

52W Low

$10.34

49.61% above

Volume

242.10K

Avg 402.36K

P/B

3.63

Price-to-book

ROE

N/A

Return on equity

Free Float

92.72%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aurinia Pharmaceuticals Inc (AUPH) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AUPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.40%

-3.19%

-2.34%

+8.71%

YTD

-3.01%

+27.96%

+61.48%

+1.98%

Financials & Valuation

TTM · Annual

Total Revenue	$283.06M
Net Income	$287.20M
Revenue Growth (YoY)	+18.87%
Gross Margin	88.46%
Operating Margin	37.65%
Net Profit Margin	101.47%
ROE	N/A
ROA · ROIC	17.53% · 54.19%

P/E Ratio	6.76
Forward P/E (FY1)	13.92
PEG Ratio	0.00
P/S	7.82
P/B	3.63
P/FCF	16.34
EPS Growth	+19.26%
Outstanding Shares	133.05M

Technical Indicators

50-Day SMA	$15.91
200-Day SMA	$15.34
RSI (14)	53.09
Beta	1.40
52-Week High	$19.24
52-Week Low	$10.34

Volume Today	242.10K
Avg Daily Volume (30D)	402.36K
Relative Volume	0.60x
Volatility (10D)	40.23
Volatility (30D)	36.73
Free Float	92.72%

Analyst Consensus

BUY

Current Price $15.47

Mean Target $17.00

52W Low$10.34 52W High$19.24

Current

Target

$10.34 $19.24

Current Analyst target

+9.89% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S68013

ISINCA05156V1022

CountryCanada

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.